AbbVie Inc. $ABBV Shares Sold by SLT Holdings LLC

SLT Holdings LLC decreased its position in AbbVie Inc. (NYSE:ABBV) by 72.1% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 1,285 shares of the company’s stock after selling 3,324 shares during the period. SLT Holdings LLC’s holdings in AbbVie were worth $336,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Walser Wealth Management Company A Ltd Liability Co boosted its holdings in shares of AbbVie by 13.4% during the third quarter. Walser Wealth Management Company A Ltd Liability Co now owns 2,305 shares of the company’s stock worth $603,000 after purchasing an additional 272 shares during the period. Uptown Financial Advisors LLC grew its stake in shares of AbbVie by 2.3% in the third quarter. Uptown Financial Advisors LLC now owns 1,957 shares of the company’s stock worth $512,000 after purchasing an additional 44 shares during the last quarter. V Square Quantitative Management LLC increased its holdings in AbbVie by 11.2% during the 3rd quarter. V Square Quantitative Management LLC now owns 12,467 shares of the company’s stock valued at $3,261,000 after purchasing an additional 1,256 shares during the period. YANKCOM Partnership increased its holdings in AbbVie by 0.5% during the 3rd quarter. YANKCOM Partnership now owns 10,217 shares of the company’s stock valued at $2,673,000 after purchasing an additional 54 shares during the period. Finally, Fortitude Advisory Group L.L.C. increased its holdings in AbbVie by 1.4% during the 3rd quarter. Fortitude Advisory Group L.L.C. now owns 5,787 shares of the company’s stock valued at $1,514,000 after purchasing an additional 80 shares during the period. 70.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ABBV has been the subject of a number of recent analyst reports. Citigroup upped their price target on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research report on Wednesday, July 15th. Barclays lifted their price objective on AbbVie from $275.00 to $300.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Guggenheim reissued a “buy” rating and set a $288.00 target price on shares of AbbVie in a research note on Friday, October 9th. BMO Capital Markets upped their target price on AbbVie from $258.00 to $300.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Finally, Leerink Partners raised their price target on AbbVie from $245.00 to $279.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $277.18.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive Phase 3 cancer-trial results provided the most important company-specific catalyst. AbbVie and Genmab reported that epcoritamab plus R-CHOP significantly reduced the risk of disease progression or death in newly diagnosed diffuse large B-cell lymphoma, strengthening AbbVie’s oncology pipeline and potential long-term growth. What Does AbbVie (ABBV) 51% DLBCL Risk Reduction Mean For Its Oncology Push?
• Positive Sentiment: Analyst and options-market confidence remains favorable. Erste Group Bank issued a positive earnings outlook, Royal Bank of Canada reaffirmed its Outperform rating, and traders purchased an unusually high volume of ABBV call options—signals of bullish expectations ahead of results. Erste Group Bank Issues Positive Outlook for AbbVie Earnings
• Positive Sentiment: Investors continue to view AbbVie as attractively valued for a large-cap pharmaceutical company. Coverage highlights a forward P/E near 16.4, strong year-to-date performance, a durable dividend, and newer medicines growing fast enough to offset declining Humira revenue. AbbVie is Outperforming the Market this Year So Far. Is Its 16.4x Valuation Attractive?
• Positive Sentiment: Sector rotation is helping the stock. Investors have been shifting toward defensive pharmaceutical companies as technology stocks weaken, pushing major drugmakers close to record highs. Big Pharma Stocks Close Near All-Time Highs
• Neutral Sentiment: Investors are now looking ahead to AbbVie’s third-quarter earnings report, scheduled for October 30. The results and updated guidance will test whether recent pipeline momentum and newer-drug growth justify the stock’s rally. AbbVie’s Q3 2026 Earnings: What to Expect
• Negative Sentiment: The primary risk remains the transition away from established blockbusters. AbbVie must prove that newer medicines can sustain earnings as mature products face competition, while its trailing valuation appears elevated despite a more reasonable forward multiple. AbbVie vs. Merck: Which Pharma Stock Offers Better Value?

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.06% of the company’s stock.

AbbVie Stock Up 0.7%

Shares of ABBV traded up $1.92 during trading hours on Friday, reaching $285.32. 5,775,785 shares of the company traded hands, compared to its average volume of 4,980,235. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $291.40. The company’s fifty day moving average price is $262.74 and its two-hundred day moving average price is $239.22. The company has a market capitalization of $504.10 billion, a price-to-earnings ratio of 80.60, a price-to-earnings-growth ratio of 1.29 and a beta of 0.24.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the prior year, the firm earned $2.97 earnings per share. AbbVie’s revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, analysts expect that AbbVie Inc. will post 13.94 EPS for the current year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a $1.73 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.4%. AbbVie’s dividend payout ratio is currently 195.48%.

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.